Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors ; volume:10 ; number:1 ; day:11 ; month:1 ; year:2024 ; pages:1-11 ; date:12.2024
Cardio-Oncology ; 10, Heft 1 (11.1.2024), 1-11, 12.2024

Creator: Perelman, Moran Gvili
Brzezinski, Rafael Y.
Waissengrin, Barliz
Leshem, Yasmin
Bainhoren, Or
Rubinstein, Tammi Arbel
Perelman, Maxim
Rozenbaum, Zach
Havakuk, Ofer
Topilsky, Yan
Banai, Shmuel
Wolf, Ido
Laufer-Perl, Michal

Contributor: SpringerLink (Online service)

DOI: 10.1186/s40959-023-00199-6

URN: urn:nbn:de:101:1-2024032512211985064616

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:46 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Perelman, Moran Gvili
Brzezinski, Rafael Y.
Waissengrin, Barliz
Leshem, Yasmin
Bainhoren, Or
Rubinstein, Tammi Arbel
Perelman, Maxim
Rozenbaum, Zach
Havakuk, Ofer
Topilsky, Yan
Banai, Shmuel
Wolf, Ido
Laufer-Perl, Michal
SpringerLink (Online service)

Other Objects (12)

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review

Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential

Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review

Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors

Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)

$Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction$

Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction

Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review

Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential

Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review

Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors

Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)

$Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction$

Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction

Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review

Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential

Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review

Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors

Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)

$Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction$

Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction

Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review

Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential

Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review

Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors

Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)

Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction

Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review

Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential

Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review

Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors

Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)

Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction

Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review

Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential

Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review

Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors

Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)

Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction

Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Related objects

Reset password